The Eyes Have It: New Ophthalmology Services for Drug Discovery and Toxicology
Thursday, February 25, 2010
11:00 AM – 12:00 PM ET (60 minutes)
The field of ophthalmology offers significant growth potential in disease areas such as Age-Related Macular Degeneration (AMD), diabetic retinopathy, and dry eye. Currently, there are millions of patients with unmet ophthalmic needs and millions more diagnosed with ocular conditions each year. In response to the requests of its sponsors, MPI Research has expanded its ophthalmic services through a partnership with Ophthy-DS, Inc., an ocular contract research organization. MPI Research now offers a suite of established animal models of ocular disease, the expertise to develop new ophthalmic models, and access to cutting-edge equipment specifically designed to document and measure pathology within the eye. These new capabilities will complement the current toxicology and experimental therapeutic capabilities MPI Research provides to its Sponsors.
In this webinar, Dr. Jamison will present a comprehensive overview of the relevance and utility of current ophthalmic models. New services under development, such as blue light phototoxicity, laser induced neovascularization, VEGF induced vascular leakage, dry eye models and ocular irritation, will also be discussed. Novel non-invasive assays used to measure the efficacy of treatment, as well as provide toxicological screening such as Electroretinagraphy (ERG) and ocular imaging of cornea, fundus, retina (OCT) and vasculature will be addressed in detail. Click here to learn more.